Board of Directors
Jim Fox joined the Board of Biota Pharmaceuticals on 9 November 2012 and has been Chairman of the Board of Biota Holdings Limited since 2009.
Dr Fox is a successful businessman with strong financial and commercial skills. He has significant experience in commercialising innovative technologies and growing a global business.
He was formerly CEO of Vision Systems, a Melbourne based technology development company, which he led until its takeover by a large US based company, Danaher. Dr Fox is a Director of Air New Zealand Limited, GenMark Diagnostics Inc, MS Research Ltd and The Technology Partnership PLC.
Dr Fox received his Bachelor, Masters and PhD degrees in engineering from the University of Melbourne.
Jim is Chairman of the Board.
Russell H. Plumb was appointed Chief Executive Officer and President on 12 November 2012.
Mr Plumb served as President, Chief Executive Officer and Chief Financial Officer of Inhibitex Inc., a US publicly-traded, clinical-stage drug development company, from December 2006 through February 2012, when it was acquired by Bristol-Myers Squibb for approximately $2.5 billion. Prior to its acquisition, Inhibitex focused its resources in recent years on developing antiviral, small molecules, including compounds to treat hepatitis C virus (HCV). From 2000 to December 2006, Mr Plumb was the Chief Financial Officer of Inhibitex, during which time he oversaw numerous financing transactions, including the company's initial public offering in 2004.
Mr Plumb has received designations as a certified public accountant in Michigan and Georgia. Mr Plumb received both a BComm and an MBA from the University of Toronto.
Dr Geoffrey F. Cox has been a Director since 2000.
Dr Cox is a partner with Red Sky Partners LLC and a member of the board of directors of QLT Inc. Dr Cox served as Chairman of the Board, President and Chief Executive Officer of GTC Biotherapeutics, Inc., a biopharmaceutical company, from 2001 to 2010. From 1997 to 2001, he was Chairman of the Board and Chief Executive Officer of Aronex Pharmaceuticals, Inc., a biotechnology company. From 1984 to 1997, he was employed by Genzyme Corporation, a biotechnology company, last serving as its Executive Vice President, Operations. Dr Cox is Chairman of the Board of the Massachusetts Biotechnology Council (MassBio) and served for a number of years on the Board of the Biotechnology Industries Association (BIO), together with the Health Governing Sections and Emerging Companies Sections of BIO.
Dr Cox received a BSc in Biochemistry from the University of Birmingham, United Kingdom, and a PhD in Biochemistry from the University of East Anglia, United Kingdom.
Richard Hill was appointed a Director of Biota Pharmaceuticals on 9 November 2012 and has been a Director of Biota Holdings Limited since 2008.
Mr Hill is currently Chairman of Sirtex Medical Limited and Calliden Group Limited and a Director of Blackwall Property Funds Limited. He was a founding partner of Hill Young & Associates and formerly held a number of senior executive positions in Hong Kong and New York with Wardley Holdings Limited, a wholly owned subsidiary of Hong Kong & Shanghai Banking Corporation (HSBC). He is an Attorney in New York State, USA and holds a BA LLB (Sydney) and LLM (London).
Ms. VanLent was appointed a Director of Biota Pharmaceuticals in May 2013. Ms. VanLent is currently the President of AMV Advisors, an advisory firm which she founded in 2008 to provide corporate strategy and financial consulting services to emerging growth life science companies. Previously, Ms. VanLent was Executive Vice President and Chief Financial Officer of Barrier Therapeutics, Inc. Prior to that, she was Executive Vice President, Portfolio Management for Sarnoff Corporation, a multidisciplinary research and development firm. Earlier in her career, she served as Senior Vice President and Chief Financial Officer of The Liposome Company, Inc. Ms. VanLent also currently serves as a member of the Board of Directors of Integra LifeSciences, Aegerion Pharmaceuticals, and Tranzyme Pharma, the latter two of which she serves as Chair of the Audit Committee. She previously served as a member of the Board of Directors of i-STAT Corporation and Penwest Pharmaceuticals.
Mr. Dougherty was appointed a Director of Biota Pharmaceuticals in May 2013. Formely, Mr. Dougherty was Chief Executive Officer of Kalidex Pharmaceuticals, a privately-held, venture-backed infectious disease company. Prior to Kalidex, he served as Chief Executive Officer and a director of Adolor Corporation, a biopharmaceutical company acquired by Cubist Pharmaceuticals in 2011. He also served in other executive roles at Adolor before being appointed CEO, including Chief Operating Officer, Chief Financial Officer, and Senior Vice President, Commercial Operations. Prior to joining Adolor, he served in a number of executive roles, including Chief Operating Officer of Genomics Collaborative, Chief Executive Officer, Chief Financial Officer and a director of Genaera Corp, and Chief Financial Officer of Centocor, Inc. Mr. Dougherty currently serves on the Board and Chairs the Audit Committee of ViroPharma, Inc.
John P. Richard, age 55, has served as a member of our Board of Directors since August 2013. Since June 2005, Mr. Richard has been a managing director of Georgia Venture Partners, LLC, a venture capital firm that focuses on the biotechnology industry. Mr. Richard has served on the board of directors of Targacept, Inc. since November 2002. He has also served as senior business adviser to Agennix AG, a biotechnology company, since April 1999 and as a non-executive director of Phase4 Ventures Limited, a private equity fund, since March 2011. From 2008 until March 2011, Mr. Richard served as a venture partner of Nomura Phase4 Ventures LP. In addition, Mr. Richard currently serves and from time-to -time during at least the past five years has served as a consultant to portfolio companies of Georgia Venture Partners, as well as to Nomura Phase4 Ventures (or an affiliated entity) and certain of its portfolio companies. Within the past five years, Mr. Richard served as a member of the board of directors of the formerly publicly-traded company Altus Pharmaceuticals Inc. Mr. Richard’s extensive executive, venture capital and business development experience, having led that function at several life science companies and establishing numerous pharmaceutical alliances, led to the conclusion that he should serve on the Company’s Board of Directors.
Stock transaction information provided by EDGAR Online. Biota Pharmaceuticals, Inc. makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.